drugset / Trial / NCT01208922

Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea

NCT01208922

Phase 3 Completed 835 enrolled Dr. Falk Pharma GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.

Timeline

Start
2010-11
Primary completion
2016-01
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ciprofloxacin Small molecule 500 mg Oral
Subject Rifamycin SV MMX Unknown 400 mg Oral

Indications